Key clinical point: Baseline gene expression predicted tyrosine kinase inhibitor 5-year responder status in chronic myeloid leukemia patients.
Major finding: A gene-expression model predicted 5-year responder status (area under the curve, 0.76).
Study details: A exploratory analysis of 70 patient samples from the ENESTnd trial.
Disclosures: The study was sponsored by Novartis. Dr. Radich is a paid consultant for Genentech, Cepheid, Bristol-Myers Squibb, Takeda, and Novartis.
Radich JP et al. SOHO 2020, Abstract CML-109.
This Week's Must Reads
Must Reads in CML
Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.